Armata Pharmaceuticals, Inc. (ARMP)
USD 1.95
(-2.5%)
USD 1.95
(-2.5%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -1.91 USD | -76.85% |
| 2022 | -1.08 USD | -12.5% |
| 2021 | -0.96 USD | 30.94% |
| 2020 | -1.39 USD | 42.8% |
| 2019 | -2.43 USD | 72.7% |
| 2018 | -8.90 USD | 68.37% |
| 2017 | -28.14 USD | 89.5% |
| 2016 | -268.06 USD | -1907.94% |
| 2015 | -13.35 USD | -102.27% |
| 2014 | 589.40 USD | 114.59% |
| 2013 | -4040.33 USD | -2397.73% |
| 2012 | -161.76 USD | 0.0% |
| 2008 | -7270.18 USD | -6.26% |
| 2007 | -6842.17 USD | 71.86% |
| 2006 | -24.31 Thousand USD | -54.89% |
| 2005 | -15.69 Thousand USD | -24.97% |
| 2004 | -12.56 Thousand USD | -873.62% |
| 2003 | -1290.16 USD | 50.31% |
| 2002 | -2596.63 USD | 16.04% |
| 2001 | -3092.77 USD | 51.0% |
| 2000 | -6312.01 USD | -52.1% |
| 1999 | -4149.83 USD | -154.09% |
| 1998 | -1633.19 USD | 53.55% |
| 1997 | -3515.72 USD | 55.63% |
| 1996 | -7924.41 USD | -68.57% |
| 1995 | -4700.85 USD | 32.85% |
| 1994 | -7000.00 USD | -3479.1% |
| 1993 | -195.58 USD | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q1 | -0.69 USD | -25.45% |
| 2024 Q2 | 0.25 USD | 42.03% |
| 2023 FY | - USD | -76.85% |
| 2023 Q1 | -0.49 USD | -68.97% |
| 2023 Q2 | -0.10 USD | 79.94% |
| 2023 Q4 | -0.55 USD | 36.05% |
| 2023 Q3 | -0.86 USD | -774.87% |
| 2022 Q2 | -0.26 USD | 13.33% |
| 2022 FY | - USD | -12.5% |
| 2022 Q1 | -0.30 USD | -20.0% |
| 2022 Q4 | -0.29 USD | -20.83% |
| 2022 Q3 | -0.24 USD | 7.69% |
| 2021 Q3 | -0.22 USD | 12.0% |
| 2021 Q4 | -0.25 USD | -13.64% |
| 2021 Q1 | -0.27 USD | 32.5% |
| 2021 Q2 | -0.25 USD | 7.41% |
| 2021 FY | - USD | 30.94% |
| 2020 Q2 | -0.26 USD | 46.94% |
| 2020 Q3 | -0.31 USD | -19.23% |
| 2020 Q4 | -0.40 USD | -29.03% |
| 2020 FY | - USD | 42.8% |
| 2020 Q1 | -0.49 USD | -2.08% |
| 2019 Q1 | -0.78 USD | 75.55% |
| 2019 FY | - USD | 72.7% |
| 2019 Q2 | -0.56 USD | 28.21% |
| 2019 Q3 | -0.73 USD | -30.36% |
| 2019 Q4 | -0.48 USD | 34.25% |
| 2018 Q2 | -2.59 USD | 21.52% |
| 2018 FY | - USD | 68.37% |
| 2018 Q4 | -3.19 USD | -811.43% |
| 2018 Q3 | -0.35 USD | 86.49% |
| 2018 Q1 | -3.30 USD | 36.05% |
| 2017 Q2 | -16.90 USD | 37.62% |
| 2017 Q4 | -5.16 USD | -319.51% |
| 2017 Q1 | -27.09 USD | 72.42% |
| 2017 FY | - USD | 89.5% |
| 2017 Q3 | -1.23 USD | 92.72% |
| 2016 Q1 | -74.05 USD | -28.29% |
| 2016 FY | - USD | -1907.94% |
| 2016 Q3 | -29.90 USD | 51.52% |
| 2016 Q4 | -98.24 USD | -228.56% |
| 2016 Q2 | -61.68 USD | 16.7% |
| 2015 Q3 | -42.00 USD | -123.62% |
| 2015 Q2 | 177.80 USD | 137.21% |
| 2015 Q1 | -477.89 USD | -3784.58% |
| 2015 FY | - USD | -102.27% |
| 2015 Q4 | -57.72 USD | -37.43% |
| 2014 Q2 | 516.60 USD | 232.8% |
| 2014 Q3 | 781.20 USD | 51.22% |
| 2014 Q4 | 12.97 USD | -98.34% |
| 2014 FY | - USD | 114.59% |
| 2014 Q1 | -389.02 USD | -184.83% |
| 2013 Q3 | -3441.79 USD | -204.36% |
| 2013 Q4 | 458.60 USD | 113.32% |
| 2013 Q2 | -1130.82 USD | -557.03% |
| 2013 Q1 | -172.11 USD | 0.0% |
| 2013 FY | - USD | -2397.73% |
| 2012 FY | - USD | 0.0% |
| 2009 Q1 | -612.22 USD | 83.92% |
| 2009 Q2 | 2519.98 USD | 511.61% |
| 2009 Q3 | 210.00 USD | -91.67% |
| 2008 Q3 | -931.40 USD | 30.26% |
| 2008 FY | - USD | -6.26% |
| 2008 Q4 | -3806.67 USD | -308.7% |
| 2008 Q1 | -1206.01 USD | 43.97% |
| 2008 Q2 | -1335.56 USD | -10.74% |
| 2007 Q1 | -2088.19 USD | -461.3% |
| 2007 Q2 | -2186.42 USD | -4.7% |
| 2007 Q3 | -1071.02 USD | 51.01% |
| 2007 Q4 | -2152.31 USD | -100.96% |
| 2007 FY | - USD | 71.86% |
| 2006 Q1 | -2945.54 USD | -1.5% |
| 2006 Q2 | -19.81 Thousand USD | -572.62% |
| 2006 Q4 | 577.97 USD | 125.6% |
| 2006 Q3 | -2257.61 USD | 88.61% |
| 2006 FY | - USD | -54.89% |
| 2005 Q2 | -4328.70 USD | -13.31% |
| 2005 FY | - USD | -24.97% |
| 2005 Q3 | -4646.77 USD | -7.35% |
| 2005 Q1 | -3820.11 USD | -94.87% |
| 2005 Q4 | -2901.88 USD | 37.55% |
| 2004 Q3 | -2336.19 USD | 38.84% |
| 2004 Q4 | -1960.35 USD | 16.09% |
| 2004 Q1 | -4666.67 USD | -750.56% |
| 2004 Q2 | -3819.74 USD | 18.15% |
| 2004 FY | - USD | -873.62% |
| 2003 Q2 | -668.89 USD | -715.02% |
| 2003 Q4 | -548.66 USD | -762.0% |
| 2003 FY | - USD | 50.31% |
| 2003 Q1 | -82.07 USD | 87.67% |
| 2003 Q3 | -63.65 USD | 90.48% |
| 2002 FY | - USD | 16.04% |
| 2002 Q1 | -725.73 USD | 21.0% |
| 2002 Q2 | -728.91 USD | -0.44% |
| 2002 Q3 | -543.33 USD | 25.46% |
| 2002 Q4 | -665.36 USD | -22.46% |
| 2001 Q3 | -792.44 USD | -18.83% |
| 2001 Q4 | -918.69 USD | -15.93% |
| 2001 Q2 | -666.85 USD | 7.03% |
| 2001 Q1 | -717.31 USD | 58.12% |
| 2001 FY | - USD | 51.0% |
| 2000 Q3 | -3688.02 USD | -557.45% |
| 2000 FY | - USD | -52.1% |
| 2000 Q4 | -1712.95 USD | 53.55% |
| 2000 Q2 | -560.96 USD | -27.57% |
| 2000 Q1 | -439.71 USD | 2.44% |
| 1999 FY | - USD | -154.09% |
| 1999 Q1 | -450.00 USD | -249.82% |
| 1999 Q2 | -949.93 USD | -111.1% |
| 1999 Q3 | -2270.01 USD | -138.97% |
| 1999 Q4 | -450.73 USD | 80.14% |
| 1998 Q2 | -600.04 USD | 36.84% |
| 1998 Q4 | 300.36 USD | 150.06% |
| 1998 Q3 | -599.96 USD | 0.01% |
| 1998 Q1 | -950.00 USD | 8.64% |
| 1998 FY | - USD | 53.55% |
| 1997 Q3 | -700.00 USD | 26.32% |
| 1997 Q1 | -849.93 USD | 12.86% |
| 1997 FY | - USD | 55.63% |
| 1997 Q4 | -1039.86 USD | -48.55% |
| 1997 Q2 | -950.00 USD | -11.77% |
| 1996 FY | - USD | -68.57% |
| 1996 Q4 | -975.31 USD | -8.37% |
| 1996 Q3 | -899.97 USD | 85.72% |
| 1996 Q1 | -1299.87 USD | -1.39% |
| 1996 Q2 | -6300.42 USD | -384.7% |
| 1995 Q3 | -949.91 USD | 29.63% |
| 1995 Q4 | -1282.05 USD | -34.97% |
| 1995 FY | - USD | 32.85% |
| 1995 Q1 | -1450.08 USD | 24.34% |
| 1995 Q2 | -1349.83 USD | 6.91% |
| 1994 Q4 | -1916.67 USD | -53.33% |
| 1994 FY | - USD | -3479.1% |
| 1994 Q1 | -69.03 USD | -38.48% |
| 1994 Q2 | -1349.61 USD | -1855.11% |
| 1994 Q3 | -1250.00 USD | 7.38% |
| 1993 Q4 | -49.85 USD | 0.0% |
| 1993 Q1 | -46.02 USD | 0.0% |
| 1993 FY | - USD | 0.0% |
| 1993 Q3 | -49.85 USD | 0.0% |
| 1993 Q2 | -49.85 USD | -8.32% |
| Name | Eps | Eps Difference |
|---|---|---|
| AIM ImmunoTech Inc. | -0.60 USD | -218.333% |
| Ampio Pharmaceuticals, Inc. | -10.67 USD | 82.099% |
| Actinium Pharmaceuticals, Inc. | -1.83 USD | -4.372% |
| Azitra, Inc. | -54.76 USD | 96.512% |
| Can-Fite BioPharma Ltd. | -1.79 USD | -6.704% |
| Chromocell Therapeutics Corporation | -1.28 USD | -49.219% |
| Calidi Biotherapeutics, Inc. | -1.73 USD | -10.405% |
| CEL-SCI Corporation | -0.73 USD | -161.644% |
| iBio, Inc. | -6.50 USD | 70.615% |
| Lineage Cell Therapeutics, Inc. | -0.12 USD | -1491.667% |
| MAIA Biotechnology, Inc. | -1.49 USD | -28.188% |
| Matinas BioPharma Holdings, Inc. | -5.28 USD | 63.826% |
| Navidea Biopharmaceuticals, Inc. | -0.59 USD | -223.729% |
| NovaBay Pharmaceuticals, Inc. | -138.65 USD | 98.622% |
| NanoViricides, Inc. | -0.70 USD | -172.857% |
| Oragenics, Inc. | -9.18 USD | 79.194% |
| BiomX Inc. | -5.10 USD | 62.549% |
| BiomX Inc. | -5.10 USD | 62.549% |
| Protalix BioTherapeutics, Inc. | 0.12 USD | 1691.667% |
| Palatin Technologies, Inc. | -2.02 USD | 5.446% |
| Scorpius Holdings, Inc. | -347.20 USD | 99.45% |